| Oct 23 |
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
|
| Oct 11 |
Foghorn Therapeutics Unveils Clinical Pipeline Progress
|
| Oct 10 |
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
|
| Oct 7 |
BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?
|
| Oct 3 |
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
|
| Oct 1 |
Foghorn Therapeutics to Participate in the BMO Oncology Summit
|
| Sep 16 |
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
|
| Sep 11 |
Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ...
|
| Sep 3 |
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
|
| Sep 2 |
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
|
